Clinical Trials Directory

Trials / Completed

CompletedNCT02933970

Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals

Stepped-Wedge Randomized Control Trial to Compare Integrated, Co-located, Telemedicine-based HCV Management for Individuals on Opiate Agonist Treatment Versus Usual Care Treatment of HCV of Individuals on Opiate Agonist Treatment

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
602 (actual)
Sponsor
Andrew Talal · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To compare the effectiveness of a patient-centered, opiate agonist treatment (OAT)-integrated telemedicine-based approach for management and delivery of hepatitis C virus (HCV) treatment to persons with substance use disorders (PWSUD) versus usual care, which we anticipate in most cases will be referral to an offsite location for HCV management. The effectiveness will be expressed through the primary patient centered and clinical outcome, achievement of viral eradication, defined as undetectable HCV RNA 12 weeks post-treatment cessation.

Detailed description

The study is a non-blinded stepped wedge cluster randomized controlled trial with two arms: onsite HCV management through telemedicine versus HCV management through usual care, referral to an offsite hepatitis specialist (Referral). The arm assignment is at the cluster (clinic) level. After an initial period (9 months) in which all clinics implement the control intervention (usual care), at regular intervals (i.e., the "steps") of 9 months duration each, one group of clinics is randomized to cross over from the Usual Care arm to the Telemedicine arm. The process continues until all clinics have crossed over to implement telemedicine, and thus all clinics contribute data to both interventions. In addition, patients cured of HCV are followed for two years post-treatment cessation to assess for reinfection or relapse of HCV RNA.

Conditions

Interventions

TypeNameDescription
OTHERTelemedicinePatients will be linked with the provider via two-way video-teleconferencing facilitated by an onsite OAT program staff member

Timeline

Start date
2017-02-28
Primary completion
2020-10-01
Completion
2022-11-01
First posted
2016-10-14
Last updated
2024-12-20
Results posted
2024-12-02

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02933970. Inclusion in this directory is not an endorsement.